These findings are in line with the research by Ren et al. who showed that SGLT2 promotes pancreatic cancer progression via the hnRNPK-YAP1 axis in the Hippo signaling pathway [18], and by Dutka et al. who suggested that the ability of SGLT2 inhibitors to block glucose uptake by cancer cells may be a therapeutic approach given the metabolic reprogramming in cancer cells [19]. The gene discussed is YAP1; the disease is pancreatic neoplasm.